Roche
NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
October 3, 2019Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq
NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …
Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer
October 1, 2019Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq
Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …
The world needs a better plan for cancer survival by 2030
September 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharma
Beginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …
Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis
September 30, 2019Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis
Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …
Roche bags FDA Breakthrough for Gazyva in lupus nephritis
September 18, 2019Research and Development FDA, Gazyva, Roche, lupus nephritis
The US FDA has granted Breakthrough Therapy Designation to Gazyva (obinutuzumab) for adults with lupus nephritis. The win comes on …
Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis
September 13, 2019Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …
Roche’s satralizumab succeeds in second positive study in rare CNS disease
September 12, 2019Research and Development NMOSD, Roche, satralizumab
In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial
September 2, 2019Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma
Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …
Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer
August 30, 2019Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
NHS England to fund Hemlibra for patients with severe haemophilia
August 21, 2019Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma
NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
Making things personal: Roche and personalised medicine
August 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, feature, personalised medicine, pharma
Ann Costello, Global Franchise Lead, Centralised Solutions at Roche Diagnostics, discusses the increasing need for a personalised approach to patient …
Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial
August 5, 2019Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq
Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …
Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer
July 29, 2019Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq
Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
